STOCKHOLM, Sept. 12,
2024 /PRNewswire/ -- Navamedic ASA (OSE: NAVA),
a Nordic pharma company and reliable provider of high-quality
products to hospitals and pharmacies, has partnered with Alex
Therapeutics, a digital health provider of disease and drug
companion apps, to aid in Parkinson's treatment management. The app
will be developed by Alex Therapeutics to support patients on
Flexilev®, a prescription treatment for Parkinson's disease.
The new companion app provides medication management support
that addresses the specific needs and challenges of people living
with Parkinson's disease. The app complements the next generation
dose dispenser, OraFID®, containing Flexilev®, offering a unique
combination to support patients to adhere to precise and
individualized treatment regimens.
Parkinson's disease is a neurodegenerative disorder associated
with loss of motor skills and non-motor functions such as cognitive
ability, which can make it difficult to manage treatments. Digital
health tools provide an opportunity to support patients with
functions such as reminders and treatment logs.
"We are excited to collaborate with Alex Therapeutics to
enhance the lives of Parkinson's patients through the companion
app. This partnership not only reflects our commitment to making
the treatment more accessible and manageable, but also underscores
our dedication to easing the burden that patients face in their
day-to-day care," shares Kathrine
Gamborg Andreassen, CEO of Navamedic.
CEO and Founder of Alex Therapeutics, John Drakenberg, states, "We are proud to
partner with Navamedic to bring this tailored solution to the
Parkinson's community. Our goal is to empower patients to manage
their treatments effectively, for better symptom relief and
improved quality of life."
The companion app is set to be launched in Sweden, Norway and Denmark in the coming year, with plans for
further global expansion.
About Navamedic
Navamedic ASA is a Nordic pharma company and reliable provider
of high-quality products, delivered to hospitals and through
pharmacies, meeting the specific needs of patients and consumers by
leveraging its highly scalable market access platform, leading
category competence and local knowledge. Navamedic is present in
all the Nordic countries, the Baltics and Benelux, with sales
representation in the UK and Greece. Navamedic is headquartered in
Oslo, Norway, and listed on the
Oslo Stock Exchange (ticker: NAVA). Senidose is a fully owned
subsidiary of Navamedic. For more information,
visit: www.navamedic.com
About Alex Therapeutics
Alex Therapeutics is a digital health company based in
Stockholm and Boston that partners with pharmaceutical
companies to support people with treatment and disease-related
mental health challenges through clinically validated companion
apps. Alex Therapeutics specializes in oncology and rare diseases,
which typically entail complex treatment regimes and psychological
distress. The company has a strong regulatory team to support CE
and FDA approval as well as clinical evidence generation for SaMDs.
For more information, visit: www.alextherapeutics.com
Media Contacts
Navamedic
Kathrine Gamborg Andreassen, CEO
kathrine@navamedic.com
Alex Therapeutics
Meera Montan, Director of Growth
meera.montan@alextherapeutics.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/alex-therapeutics/r/alex-therapeutics-has-signed-an-exclusive-agreement-with-navamedic-for-the-development-of-a-companio,c4036593
The following files are available for download:
https://mb.cision.com/Main/21311/4036593/2997417.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.com/news-releases/alex-therapeutics-has-signed-an-exclusive-agreement-with-navamedic-for-the-development-of-a-companion-app-to-aid-in-the-treatment-of-parkinsons-disease-302246414.html
SOURCE Alex Therapeutics